StockData

Metagenomi Therapeutics vs Relay Therapeutics

MGX and RLAY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MGX and RLAY compare

Relay Therapeutics is the larger company, worth 147 times as much as Metagenomi Therapeutics ($3.8B against $25.7M).

Relay Therapeutics scores higher on the StockData Score (10 against 6 for Metagenomi Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMGXRLAY
Size and price
Market cap$25.7M$3.8B
Share price$0.680$17.27
Change, 1 year−60.0%168%
Change, 5 years–−42.1%
Beta (5Y)1.751.89
Employees119192
StockData Score
Total score610 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score02 (better)
Health score56 (better)
Dividend score00
Valuation
P/S–366×
P/B0.2× (better)4.3×
FCF yield−334%–
Growth
Revenue growth (TTM)–23.9%
Revenue growth, 5Y average–−28.6%
Profitability
Operating margin–−2999%
Net margin–−2764%
Return on equity−60.6%−36.8% (better)
Return on invested capital–−37.1%
Financial health
Debt / equity0.000.00
Current ratio4.5018.27 (better)
Altman Z-score−3.9026.22 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions16.6%113%
Held by insiders10.4%24.5%
Insider net buying, 12 months−$9.7K (better)−$129M
Superinvestors holding–1
Short interest, % of float3.9%26.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.